New investment supports DxA’s mission to advance the development of scalable and universally accessible diagnostics. Blood tests will be key to further evolving Alzheimer’s diagnostics, care, and research. NEW YORK, Sept. 25, 2024 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.